<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2678">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501162</url>
  </required_header>
  <id_info>
    <org_study_id>EPALD</org_study_id>
    <nct_id>NCT01501162</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease</brief_title>
  <acronym>EPALD</acronym>
  <official_title>Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chuncheon Sacred Heart Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background/Aims:

      The investigators explored the therapeutic effects of probiotics in patients with AH.

      Methods:

      Between September 2010 and April 2012, the investigators conducted a 7-day,
      double-controlled, randomized, prospective clinical trial comparing the efficacy of
      probiotics in improving liver enzymes, LPS, pro-inflammatory cytokines. AH was defined as an
      aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 2 and elevated AST (ALT)
      level with an alcohol consumption history within 48 hours. Patients were randomized to
      receive 7 days of probiotics (1500 mg/day) or placebo. The levels of liver enzymes, modified
      Discriminant Function (mDF), LPS, and pro-inflammatory cytokines were checked at baseline
      and again after therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background/Aims: Alcoholic hepatitis (AH) is one of the leading causes of liver diseases.
      Gut-derived microbial lipopolysaccharide (LPS) has been known as a central role in the
      pathogenesis of AH. Some animal studies suggested an emerging role of probiotics in
      restoration of the bowel flora and improving liver enzymes. We explored the therapeutic
      effects of probiotics in patients with AH.

      Methods: Between September 2010 and April 2012, we conducted a 7-day, double-controlled,
      randomized, prospective clinical trial comparing the efficacy of probiotics in improving
      liver enzymes, LPS, pro-inflammatory cytokines. AH was defined as an aspartate
      aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 2 and elevated AST (ALT) level with
      an alcohol consumption history within 48 hours. Patients were randomized to receive 7 days
      of probiotics (1500 mg/day) or placebo. The levels of liver enzymes, modified Discriminant
      Function (mDF), LPS, and pro-inflammatory cytokines were checked at baseline and again after
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Liver Enzymes(ALT)</measure>
    <time_frame>7 days after probiotics</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood analysis was performed using standard methodologies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipopolysaccharide (LPS) and Pro-inflammatory Cytokines</measure>
    <time_frame>7 days after probiotics</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>For the measurements of cytokines, homogenates of serum were processed with Human Tumor necrosis factor-alpha ELISA Kit and Human interleukin 1 beta ELISA Kit . For the measurement of LPS ELISA Kit was used. Assays were performed according to the manufacturer's instructions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>alcohol, hepatitis, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hepatitis, alcohol, probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hepatitis, alcohol, probiotics</intervention_name>
    <description>7 days of probiotics (1500 mg/day)</description>
    <arm_group_label>hepatitis, alcohol, probiotics</arm_group_label>
    <other_name>LACTOWELL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alcohol, hepatitis, Placebo</intervention_name>
    <description>Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.</description>
    <arm_group_label>alcohol, hepatitis, Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alcoholic Hepatitis

        Exclusion Criteria:

          -  Cancer

          -  Viral Hepatitis, other Hepatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Tae Suk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <zip>200-704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>March 24, 2015</lastchanged_date>
  <firstreceived_date>December 27, 2011</firstreceived_date>
  <firstreceived_results_date>December 31, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chuncheon Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Ki Tae Suk</investigator_full_name>
    <investigator_title>doctor, assistant professor</investigator_title>
  </responsible_party>
  <keyword>hepatitis, alcohol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alcohol, Hepatitis, Placebo</title>
          <description>Placebo (for probiotics) for 7 days Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.</description>
        </group>
        <group group_id="P2">
          <title>Hepatitis, Alcohol, Probiotics</title>
          <description>7 days of probiotics (1500 mg/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alcohol, Hepatitis, Placebo</title>
          <description>Placebo (for probiotics) for 7 days Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.</description>
        </group>
        <group group_id="B2">
          <title>Hepatitis, Alcohol, Probiotics</title>
          <description>7 days of probiotics (1500 mg/day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="117"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="117"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53.8" spread="12.4"/>
                <measurement group_id="B2" value="52.7" spread="9.4"/>
                <measurement group_id="B3" value="52.7" spread="11.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="75"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="117"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver Enzymes(ALT)</title>
        <description>Blood analysis was performed using standard methodologies.</description>
        <time_frame>7 days after probiotics</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcohol, Hepatitis, Placebo</title>
            <description>Placebo (for probiotics) for 7 days Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis, Alcohol, Probiotics</title>
            <description>7 days of probiotics (1500 mg/day)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Liver Enzymes(ALT)</title>
            <description>Blood analysis was performed using standard methodologies.</description>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66" spread="136"/>
                  <measurement group_id="O2" value="48" spread="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipopolysaccharide (LPS) and Pro-inflammatory Cytokines</title>
        <description>For the measurements of cytokines, homogenates of serum were processed with Human Tumor necrosis factor-alpha ELISA Kit and Human interleukin 1 beta ELISA Kit . For the measurement of LPS ELISA Kit was used. Assays were performed according to the manufacturer's instructions.</description>
        <time_frame>7 days after probiotics</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcohol, Hepatitis, Placebo</title>
            <description>Placebo (for probiotics) for 7 days Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis, Alcohol, Probiotics</title>
            <description>7 days of probiotics (1500 mg/day)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Lipopolysaccharide (LPS) and Pro-inflammatory Cytokines</title>
            <description>For the measurements of cytokines, homogenates of serum were processed with Human Tumor necrosis factor-alpha ELISA Kit and Human interleukin 1 beta ELISA Kit . For the measurement of LPS ELISA Kit was used. Assays were performed according to the manufacturer's instructions.</description>
            <units>EU/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" spread="2.7"/>
                  <measurement group_id="O2" value="1.7" spread="1.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and Other (Not Including Serious) Adverse Events were not collected/assessed</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alcohol, Hepatitis, Placebo</title>
          <description>Placebo (for probiotics) for 7 days Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.</description>
        </group>
        <group group_id="E2">
          <title>Hepatitis, Alcohol, Probiotics</title>
          <description>7 days of probiotics (1500 mg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ki Tae Suk</name_or_title>
      <organization>Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea</organization>
      <phone>+82-33-240-5826</phone>
      <email>ktsuk@hallym.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
